Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
22/10/2026 23:22
BRIEF-Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results Oct 22 (Reuters) - Vicore Pharma Holding AB VICOR.ST:
VICORE PHARMA HOLDING AB: PHASE 2B ASPIRE TRIAL OF BULOXIBUTID IN IPF PASSES PRE-PLANNED FUTILITY ANALYSIS, ON TRACK FOR MID-2027 TOPLINE RESULTS
VICORE PHARMA HOLDING AB: INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS ASPIRE CONTINUE WITHOUT MODIFICATION; NO SAFETY CONCERNS IDENTIFIED
Source text: [ID:n0001437749-26-033290]
Further company coverage: VICOR.ST
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2